The FDA issued an Emergency Use Authorization for Simparica TRIO (sarolaner, moxidectin, and pyrantel) to treat New World screwworm infestations in dogs and puppies on August 13, 2026. The authorization applies to dogs in high-risk geographic areas, particularly those traveling to or returning from regions south of the U.S. border where screwworm has been detected.
Simparica Trio Gets Screwworm EUA—Zoetis Wins
FDA emergency authorization for parasitic treatment expands Zoetis' veterinary portfolio.

Zoetis locks in exclusive emergency authorization for screwworm treatment—first-mover advantage in a niche but growing veterinary market.
Who cashes in: Zoetis ZTS, the manufacturer of Simparica TRIO, gains exclusive access to a new indication in a growing veterinary parasiticide market. The EUA removes regulatory friction and allows immediate commercialization without waiting for full approval. Veterinary clinics and animal hospitals that treat infected dogs also benefit from having a branded, FDA-authorized option to offer clients. Pet owners in border states and those traveling internationally represent a defined customer base willing to pay premium prices for emergency treatment.
Who's exposed: Generic and off-label parasiticide treatments face displacement as veterinarians and pet owners prefer an FDA-authorized product. Competitors offering older or less-targeted screwworm treatments (if any exist in the U.S. market) lose share. The exposure is modest because screwworm is geographically limited and relatively rare in the U.S., but Zoetis' brand strength and distribution network ensure rapid adoption in affected regions.
What to watch next: Geographic spread of screwworm cases and uptake rates among veterinarians in high-risk areas. If screwworm becomes endemic in more U.S. states, Zoetis' addressable market expands significantly and could justify a full approval application.
Source: original report ↗
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.